A systematic review of real-world healthcare resource use and costs of Clostridioides difficile infections

被引:7
作者
Malone, Daniel C. [1 ,2 ]
Armstrong, Edward P. [1 ,3 ]
Gratie, Dan [4 ]
Pham, Sissi V. [4 ]
Amin, Alpesh [5 ,6 ]
机构
[1] Strateg Therapeut LLC, Tucson, AZ 85737 USA
[2] Univ Utah, Coll Pharm, Salt Lake City, UT USA
[3] Univ Arizona, Coll Pharm, Tucson, AZ 85721 USA
[4] AESARA, Chapel Hill, NC USA
[5] Univ Calif Irvine, Med Business Publ Hlth Nursing Sci & Biomed Engn, Irvine, CA USA
[6] Univ Calif Irvine, Hospitalist Program, Irvine, CA USA
来源
ANTIMICROBIAL STEWARDSHIP & HEALTHCARE EPIDEMIOLOGY | 2023年 / 3卷 / 01期
关键词
LENGTH-OF-STAY; HOSPITAL COSTS; ECONOMIC BURDEN; UNITED-STATES; RECURRENT; MORTALITY; IMPACT; RISK;
D O I
10.1017/ash.2022.369
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objective: To conduct a systematic review of published real-world evidence describing the cost and healthcare resource use for Clostridiodes difficile infection (CDI) in the United States. Methods: A systematic literature review was conducted searching for terms for CDI and healthcare costs. Titles of articles and abstracts were reviewed to identify those that met study criteria. Studies were evaluated to examine overall design and comparison groups in terms of healthcare resource use and cost for CDI. Results: In total, 28 articles met the inclusion criteria. Moreover, 20 studies evaluated primary CDI or did not specify, and 8 studies(1-8) evaluated both primary CDI and recurrent (rCDI). Data from Medicare were used in 6 studies. Nearly all studies used a comparison group, either controls without CDI (N = 20) or comparison between primary CDI and rCDI (N = 7). Two studies examined costs of rCDI by the number of recurrences. Overall, the burden of CDI is significant, with higher aggregate costs for patients with rCDI. Compared with non-CDI controls, hospital length of stay increased in patients with both primary and rCDI compared to patients without CDI. Patients with primary CDI cost healthcare systems $24,000 more than patients without CDI. Additionally, 2 studies that evaluated the impact of recurrence among those patients with an index case of CDI demonstrated significantly higher direct all-cause medical costs among those with rCDI compared to those without. Conclusion: CDI, and particularly rCDI, is a costly condition with hospitalizations being the main cost driver.
引用
收藏
页数:8
相关论文
共 40 条
  • [1] Clinical Predictors of Recurrence After Primary Clostridioides difficile Infection: A Prospective Cohort Study
    Allegretti, Jessica R.
    Marcus, Jenna
    Storm, Margaret
    Sitko, Jessica
    Kennedy, Kevin
    Gerber, Georg K.
    Bry, Lynn
    [J]. DIGESTIVE DISEASES AND SCIENCES, 2020, 65 (06) : 1761 - 1766
  • [2] Bezlotoxumab for the prevention of Clostridium difficile infection: a review of current evidence and safety profile
    Alonso, Carolyn D.
    Mahoney, Monica V.
    [J]. INFECTION AND DRUG RESISTANCE, 2019, 12 : 1 - 9
  • [3] Campbell Rebecca, 2013, J Med Econ, V16, P440, DOI 10.3111/13696998.2013.770749
  • [4] Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial
    Cornely, Oliver A.
    Crook, Derrick W.
    Esposito, Roberto
    Poirier, Andre
    Somero, Michael S.
    Weiss, Karl
    Sears, Pamela
    Gorbach, Sherwood
    [J]. LANCET INFECTIOUS DISEASES, 2012, 12 (04) : 281 - 289
  • [5] Drozd Edward M, 2015, Infect Dis Clin Pract (Baltim Md), V23, P318
  • [6] Attributable Inpatient Costs of Recurrent Clostridium difficile Infections
    Dubberke, Erik R.
    Schaefer, Eric
    Reske, Kimberly A.
    Zilberberg, Marya
    Hollenbeak, Christopher S.
    Olsen, Margaret A.
    [J]. INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2014, 35 (11) : 1400 - 1407
  • [7] The economic burden of Clostridioides difficile infection in patients with hematological malignancies in the United States: A case-control study
    Duhalde, Lola
    Lurienne, Lise
    Wingen-Heimann, Sebastian M.
    Guillou, Lucien
    Buffet, Renaud
    Bandinelli, Pierre-Alain
    [J]. INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2020, 41 (07) : 813 - 819
  • [8] Risk of complications and mortality following recurrent and non-recurrent Clostridioides difficile infection: a retrospective observational database study in England
    Enoch, D. A.
    Murray-Thomas, T.
    Adomakoh, N.
    Dedman, D.
    Georgopali, A.
    Francis, N. A.
    Karas, A.
    [J]. JOURNAL OF HOSPITAL INFECTION, 2020, 106 (04) : 793 - 803
  • [9] Healthcare resource utilization and direct medical costs associated with index and recurrent Clostridioides difficile infection: a real-world data analysis
    Feuerstadt, Paul
    Stong, Laura
    Dahdal, David N.
    Sacks, Naomi
    Lang, Kathleen
    Nelson, Winnie W.
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (06) : 603 - 609
  • [10] Clinical and Economic Benefits of Fidaxomicin Compared to Vancomycin for Clostridium difficile Infection
    Gallagher, Jason C.
    Reilly, Joseph P.
    Navalkele, Bhagyashri
    Downham, Gemma
    Haynes, Kevin
    Trivedi, Manish
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (11) : 7007 - 7010